Capitolis Advisors’s Zimmer Biomet ZBH Stock Holding History

Capitolis Advisors’s Portfolio ZBH Stock Details ZBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-8,409	Closed	-$1.04M	–	505
2021 Q4	$1.04M	Buy	+8,409	New	+$1.1M	0.01%	480
2021 Q2	–	Sell	-12,426	Closed	-$1.93M	–	482
2021 Q1	$1.93M	Hold	12,426	–	–	0.03%	253
2020 Q4	$1.86M	Buy	+12,426	New	+$1.76M	0.03%	326

Other funds holding ZBH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capitolis Advisors's ZBH Position: Q1 2022 in Review

Capitolis Advisors sold out of Zimmer Biomet (ZBH) in Q1 2022, closing a stake of 8,409 shares — an estimated $1.04M sold.

Capitolis Advisors first reported a position in ZBH in Q4 2020 and held it in 3 quarters. The position peaked at $1.93M in Q1 2021. 977 funds tracked by Wall St. Rank hold ZBH as of Q1 2022.

Capitolis Advisors reported no remaining Zimmer Biomet position as of Q1 2022 after selling out during the quarter.
Capitolis Advisors sold 8,409 Zimmer Biomet shares in Q1 2022, an estimated $1.04M.
Capitolis Advisors first reported a position in Zimmer Biomet in Q4 2020 and held it in 3 quarters.
Capitolis Advisors's Zimmer Biomet position peaked at $1.93M in Q1 2021.
977 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2022.

Based on Capitolis Advisors's 13F filing for Q1 2022, filed 12 May 2022.